MedPath

To evaluate the Safety and efficacy of a Unani formulations in the treatment of Zahīr (Dysentery)

Phase 2
Conditions
Health Condition 1: A060- Acute amebic dysentery
Registration Number
CTRI/2015/12/006431
Lead Sponsor
Central Council for Research in Unani Medicine New Delhi
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Open to Recruitment
Sex
Not specified
Target Recruitment
300
Inclusion Criteria

•Patients of either sex in the age group 18-65 years.

•Patients of ZahÄ«r (Dysentery) having the following signs and symptoms:

ï?§2-8 small-volume, semiformed or unformed stools/day

ï?§BarÄ?z DamwÄ« (Bloody Stools) and/or BarÄ?z MukhÄ?tÄ« (Mucoid Stools)

ï?§E. histolytica Cysts or Trophozoites in stools

With or without any of the following:

ï?§Maghs (Tenesmus)

ï?§Wajaâ?? al-Batn Asfal (Lower Abdominal Pain)

ï?§ÄªlÄ?m al-Batn Asfal (Lower Abdominal Tenderness)

Exclusion Criteria

1.Patients having diarrhoea with >8 stools/day

2.Moderate or severe dehydration

3.Fever (>=101 °F)

4.Patients having amoebic dysentery with any associated severe complications, e.g., fulminant colitis with perforation, paralytic ileus, toxic megacolon, ameboma, and liver abscess.

5.Clinical evidence of coexisting acute systemic illnesses

6.History or clinical evidence of chronic diseases requiring long-term treatment, e.g., DM, hypertension, tuberculosis, HIV infection, chronic liver disease, CKD, coeliac disease, IBD, or any other serious and/or unstable medical condition that, in the opinion of the investigator, could constitute a risk when taking study drug or could interfere with the interpretation of data.

7.Pregnant and lactating women

8.H/o Addiction (alcohol, drugs)

9.H/o Hypersensitivity to the study drug or any of its ingredients

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Improvement in signs and symptoms of Zimad e Bars of Zahīr (Dysentery)Timepoint: 2 weeks
Secondary Outcome Measures
NameTimeMethod
Haematological and biochemical assessment for safety assessmentTimepoint: 2 weeks
© Copyright 2025. All Rights Reserved by MedPath